Clinical Trials on Plasma Protein; Transport Protein

Total 5227 results

National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Danone Specialized Nutrition Indonesia

Recruiting

Tolerance of Extensive Hydrolyzed Whey Protein Milk Among Infant With Mild to Moderate CMPA (PEACE)

Mild to Moderate Cows' Milk Protein Allergy

Indonesia
Washington University School of Medicine
Kamuzu University of Health Sciences

Withdrawn

Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition

Kwashiorkor | Marasmus

Malawi
Washington University School of Medicine

Completed

Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition

Kwashiorkor | Marasmus

Malawi
Romanian Society for Enteral and Parenteral Nutrition

Not yet recruiting

ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts (ACCUMULATE)

Trauma | Gastroparesis | Muscle Loss | Metabolism | Nutritional Deficiency | Protein Malnutrition | Calorie Malnutrition Protein

Romania
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Aibin Liang，MD，Ph.D.
CARsgen Therapeutics Co., Ltd.

Recruiting

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in Relapse

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
VU University of Amsterdam
Amsterdam UMC, location VUmc; University of Helsinki

Completed

The (Cost)Effectiveness of Increasing Protein Intake on Physical Funtioning in Older Adults

Physical Disability | Protein-Energy Malnutrition

Finland, Netherlands
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
Washington University School of Medicine
University of Malawi

Completed

Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition

Kwashiorkor | Marasmus

Malawi
Camillians Saint Mary's Hospital Luodong

Unknown

Comparison of the Effects of Different Protein Diet in Hemodialysis Patients

Diffenence of Protein Diets on Hemodialysis Patients
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma

United States
NCIC Clinical Trials Group

Completed

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
University of Southampton
NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation... and other collaborators

Terminated

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant (AntiCD-66)

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NCIC Clinical Trials Group

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
University of Maryland, Baltimore
National Cancer Institute (NCI); University of Maryland Greenebaum Cancer Center

Completed

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Roswell Park Cancer Institute

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Medical Research Council

Unknown

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Oncotherapeutics

Unknown

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Oncotherapeutics

Completed

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Erasme University Hospital

Unknown

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Belgium, Poland
Leeds Cancer Centre at St. James's University Hospital

Unknown

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
The Cleveland Clinic

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
AEterna Zentaris

Completed

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Federico II University

Recruiting

Non-Immunoglobulin E-mediated Food Allergies in Children (NIGEFA)

Non IgE Mediated Food Allergy | Food Protein-Induced Enteropathy | Food Protein-Induced Proctocolitis | Food Protein-Induced Enterocolitis Syndrome | Food Protein-induced Motility Disorders

Italy
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Multiple Myeloma Research Foundation

Active, not recruiting

MMRF Molecular Profiling Protocol

Multiple Myeloma | Plasma Malignancy

United States, Canada
Rajavithi Hospital

Recruiting

Effect of Whey Protein Supplementation on Postoperative Outcomes After Gynecological Cancer Surgery

Postoperative Outcomes | Whey Protein | Gynecological Cancer Surgery

Thailand

Clinical Trials on Plasma Protein; Transport Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations